The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed drug therapies could prevent hereditary diseases. Elsewhere, there were… Read More
News round-up for 13 – 17 October by Bruno Quinney, Content Team at DDW. This week’s top story comes from new research showing drug therapies could prevent hereditary diseases. Elsewhere, there have been major developments in cancer research and gene therapy could help combat hearing loss. … Read More
New drug therapies could be developed to prevent hereditary diseases, research reveals. According to a study published in the latest issue of Science, researchers have pinpointed a cellular mechanism involved in the inheritance of genetic mutations. It is believed the findings could help develop treatments… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with CEO of… Read More
Cyxone, a Swedish clinical stage biotech company developing disease modifying therapies for diseases such as rheumatoid arthritis (RA), confirms the previously demonstrated favourable safety and tolerability profile for its drug candidate Rabeximod, in the Clinical Study Report from its exploratory Phase II study in Covid-19 patients. Other… Read More
Parkinson’s UK and Domainex have collaborated to develop small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s Disease. Context Inflammation is vital for defending the body from infections, injuries and toxins. However, in Parkinson’s there is excessive chronic inflammation within the brain. Read More
The National University Cancer Institute, Singapore (NCIS) and MiNA Therapeutics have dosed the first patients in an investigator-sponsored Phase I study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are… Read More
Terumo Blood and Cell Technologies and Immunicom have signed a co-commercialisation agreement to help advance a cancer therapy that selectively removes immune inhibitors from a patient’s bloodstream. What will this achieve? This potentially enables the patient’s immune system to more effectively attack cancer tumours. In contrast to immunotherapy pharmaceuticals… Read More
Australian clinical-stage drug development company Noxopharm has announced its DARRT-2 Phase II clinical trial has begun with patient enrollment in the US. It is said to have the potential to revolutionise cancer treatment by achieving cancer reduction without many of the unwanted side effects, cost limitations, and logistical challenges… Read More
Gedeon Richter has been granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA) for relugolix combination therapy (Ryeqo), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The decision reportedly makes the relugolix combination therapy the first oral gonadotropin-releasing hormone… Read More
Galapagos presented data at the United European Gastroenterology Week (UEGW) virtual 2021 congress, which suggests patients with ulcerative colitis (UC) treated with early advanced therapy within the first 18 months post diagnosis showed less residual diarrhoea and required fewer follow-up tests than those who were treated with an advanced therapy later. Results… Read More
Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More
Join Terrence Kenakin as he presents a two-day Applied course on September 21 and September 22 at 10AM CDT. This two-day course will introduce the topic of biologics as a drug therapy in addition to recombinant replacement protein biologics, peptide signalling, immunotherapy, antibodies features, and nucleotide-based… Read More
